patent.fyi
Applications  /  US 2026/0355221
United States Patent Application Publication

US 2026/0355221 A1

Published
Nov 12, 2026
Filed
Jul 13, 2026
Earliest date on the face
Aug 8, 2022
Classification
A61K 31/658
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Turmeric extract in liquid oil

What ifWhat if the turmeric extract is dissolved in edible oil without a dispersing agent?
Claim language“prepared with a dispersing agent”

A lipid-soluble fraction of the turmeric extract is dissolved in medium-chain triglyceride oil below its measured solubility limit. A sealed soft capsule releases the oil in the digestive tract, where bile salts emulsify it.

1.1Ready to drink liquid

What ifWhat if a premeasured liquid delivers the extracts without a solid dosage form or a powder that requires mixing?
Claim language“a capsule, a tablet, a lozenge, and a powdered drink mix”

Water-soluble extract fractions are dissolved in a water and glycerol base, and the turmeric fraction is dispersed as fine oil droplets. A sealed single-serving bottle supplies a measured volume for swallowing.

1.2Macamides as the release marker

What ifWhat if a maca extract containing 0.2% to 0.5% glucosinolates is standardized by its macamide content?
Claim language“at least 0.7% glucosinolates”

Ethanol extraction yields a lipid-rich maca fraction, and liquid chromatography measures its total macamide content. Lots are blended to a fixed macamide target and tested to confirm that glucosinolates fall within the 0.2% to 0.5% range.

1.3Concentrated ashwagandha at lower loading

What ifWhat if a concentrated ashwagandha extract makes up 2% of the composition by weight?
Claim language“between about 5% and 30%”

A 500 mg composition contains 10 mg of ashwagandha extract assayed at 25% total withanolides, yielding 2.5 mg of total withanolides per unit. Geometric dilution with microcrystalline cellulose distributes the small extract mass through the blend before encapsulation.

1.4Chlorogenic acid as release marker

What ifWhat if an artichoke extract containing less than 1% cynarin is standardized to 5% chlorogenic acid?
Claim language“at least 3% cynarin”

A hydroalcoholic leaf extract is fractionated by preparative chromatography, and fractions rich in chlorogenic acid are pooled. Liquid chromatography verifies the chlorogenic acid target and the upper limit for cynarin before the dried extract is blended into the composition.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Botanical blend for sensory panels

A food sensory laboratory uses the four-extract powdered drink mix as a reference sample for bitterness, astringency, and sediment. Technicians disperse equal masses from each lot in equal volumes of water at a fixed temperature and stir each sample for the same interval. Panelists score coded samples in randomized order, and technicians record sediment depth after a fixed standing interval.

Combination with existing systems

Drink powder in dual chamber packaging

A dual chamber bottle holds the dry four-extract blend in a dispensing cap and water in the bottle below. A pierceable membrane seals the powder chamber against moisture during storage. Pressing the cap actuator drives a plunger through the membrane, and shaking the bottle disperses the released powder in the water.

Automated or data-driven variant

Assay driven extract weighing

Batch software imports measured glucosinolate and cynarin concentrations from incoming extract lots. It checks the lots against the respective 0.7% and 3% minimums, then divides each finished-batch marker target by the measured marker mass fraction to calculate the required extract mass. The software checks the resulting extract percentages against the recipe limits and adjusts the filler mass to reach the batch target. A connected scale records the dispensed masses against the batch record.

Component substitution

Pullulan film replaces the lozenge

A water-soluble pullulan film carries the four extracts in place of a lozenge. The extracts are dispersed in an aqueous pullulan solution containing glycerol, and a doctor blade spreads the mixture onto a release liner. A dryer removes the water, and a cutter divides the dry film into pieces of uniform area. Each piece hydrates in saliva and releases the extract blend for swallowing.

Specific version of a part

Lecithin dispersed turmeric capsule

Turmeric extract is wet-milled with sunflower lecithin in water and spray-dried with maltodextrin. The resulting powder is filled into a hard capsule, with the turmeric extract solids accounting for 30% of the finished composition by weight.

Maca powder for drink mixing

Maca root extract is spray-dried and standardized to 1.0% total glucosinolates by liquid chromatography. A 2 g drink mix contains 200 mg of the standardized extract and disperses when stirred into water.

Ashwagandha immediate release tablet

A 600 mg tablet contains 90 mg of dry ashwagandha root extract. Microcrystalline cellulose supports compression, and croscarmellose sodium draws in water and swells to break up the tablet after ingestion.

Cynarin standardized artichoke capsule

Artichoke leaf extract is dried and standardized to 4% cynarin by liquid chromatography. A 500 mg finished capsule contains 75 mg of the standardized extract, which supplies 3 mg of cynarin per unit.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0271944 A1
Published
Sep 18, 2014
Filed
Mar 14, 2013
Class
A61K 36/28
Document BUS 10,172,826 B2
Published
Jan 8, 2019
Filed
May 1, 2017
Class
A61K 31/365
Claim 1
Document A
Document B
1.1one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, comprising: a Curcuma longa extract prepared with a dispersing agent, wherein the Curcuma longa extract comprises between about 15% and 55% of the composition, by weight;
According to one embodiment, the composition for use in treating oxidative stress in a subject in need thereof, comprising: a Bacopa monniera extract containing 45% bacosides, a Silybum marianum (milk thistle) extract containing 70-80% Silymarin, a Withania somnifera (ashwagandha) extract in the form of a powder, a Camellia sinensis (green tea) extract containing 98% polyphenols and 45% EGCG, and a Curcuma longa (turmeric) extract containing 95% Curcumin is administered at le
A · US 2014/0271944 A1 · ¶ 326
A dietary supplement composition formulated in a therapeutic effective amount to treat and alleviate symptoms of hot flashes in a female subject experiencing symptoms of perimenopause comprising 10 to 50 mg of a plant lignan that contains 7-hydroxymatairesinol (HMR Lignan), 2 to 10 mg of lycopene, and 40 to 80 mg of cranberry powder in an oral dosage form, wherein said dietary supplement composition is in the form of a single dosage capsule.
B · US 10,172,826 B2 · claim 1
1.2one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, comprising: a Lepidium meyenii extract standardized to comprise at least 0.7% glucosinolates, wherein the Lepidium meyenii extract comprises between about 5% and 20% of the composition, by weight;
A dietary supplement composition formulated in a therapeutic effective amount to treat and alleviate symptoms of hot flashes in a female subject experiencing symptoms of perimenopause comprising 10 to 50 mg of a plant lignan that contains 7-hydroxymatairesinol (HMR Lignan), 2 to 10 mg of lycopene, and 40 to 80 mg of cranberry powder in an oral dosage form, wherein said dietary supplement composition is in the form of a single dosage capsule.
B · US 10,172,826 B2 · claim 1
1.3one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, comprising: a Withania somnifera extract comprising between about 5% and 30% of the composition, by weight; and
According to one embodiment, the composition for use in treating oxidative stress in a subject in need thereof, comprising: a Bacopa monniera extract containing 45% bacosides, a Silybum marianum (milk thistle) extract containing 70-80% Silymarin, a Withania somnifera (ashwagandha) extract in the form of a powder, a Camellia sinensis (green tea) extract containing 98% polyphenols and 45% EGCG, and a Curcuma longa (turmeric) extract containing 95% Curcumin is administered at le
A · US 2014/0271944 A1 · ¶ 326
A dietary supplement composition formulated in a therapeutic effective amount to treat and alleviate symptoms of hot flashes in a female subject experiencing symptoms of perimenopause comprising 10 to 50 mg of a plant lignan that contains 7-hydroxymatairesinol (HMR Lignan), 2 to 10 mg of lycopene, and 40 to 80 mg of cranberry powder in an oral dosage form, wherein said dietary supplement composition is in the form of a single dosage capsule.
B · US 10,172,826 B2 · claim 1
1.4one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, comprising: a Cynara scolymus extract standardized to comprise at least 3% cynarin, wherein the Cynara scolymus extract comprises between about 1% and 30% of the composition, by weight.
A dietary supplement composition formulated in a therapeutic effective amount to treat and alleviate symptoms of hot flashes in a female subject experiencing symptoms of perimenopause comprising 10 to 50 mg of a plant lignan that contains 7-hydroxymatairesinol (HMR Lignan), 2 to 10 mg of lycopene, and 40 to 80 mg of cranberry powder in an oral dosage form, wherein said dietary supplement composition is in the form of a single dosage capsule.
B · US 10,172,826 B2 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
Specifically, the present invention is directed to the field of natural remedies and the development of compositions to increase the antioxidant potential of a subject by inducing the subject's natural cellular defenses.
A · US 2014/0271944 A1 · ¶ 2
This ability to be self-propagating makes free radicals highly toxic to living organisms, and oxidative injury may lead to widespread biochemical damage within the cell.
A · US 2014/0271944 A1 · ¶ 4
Therefore, even further improvements in remedies other than hormone replacement therapies for reducing hot flashes and other symptoms of perimenopause in women are desired.
B · US 10,172,826 B2 · ¶ 4
A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject.
B · US 10,172,826 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355221 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355221/, SHA-256 d635c05da43b5d8eb75681c3fac626d0fce21751b982409e88bc7a7dc1af97d9
First published
Permanent addresshttps://patent.fyi/US20260355221/
Content fingerprint (SHA-256)d635c05da43b5d8eb75681c3fac626d0fce21751b982409e88bc7a7dc1af97d9
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi